Drug Profile
Emiplacel - Pluri
Alternative Names: Allogeneic ex-vivo expanded placental adherent stromal cells; PLacental eXpanded cells; PLX PAD; PLX-PAD cell therapyLatest Information Update: 09 Oct 2023
Price :
$50
*
At a glance
- Originator Pluristem Therapeutics
- Developer Pluri; Tel-Aviv Ichilov Medical Center
- Class Ischaemic heart disorder therapies; Mesenchymal stem cell therapies; Stem cell therapies; Vascular disorder therapies
- Mechanism of Action Cell differentiation modulators; Cell replacements; Dendritic cell modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Chronic limb-threatening ischemia; Muscle injury
- Phase II Intermittent claudication; SARS-CoV-2 acute respiratory disease
- Phase I/II Graft-versus-host disease
- No development reported Duchenne muscular dystrophy; Ischaemic heart disorders; Preeclampsia; Pulmonary arterial hypertension; Tendon injuries; Thromboangiitis obliterans
Most Recent Events
- 06 Sep 2023 Pluristem completes a phase III trial for Muscle injury (In the elderly, In adults, In neonates, In infants, In children, In adolescents) in USA, Bulgaria, Denmark, Germany, United Kingdom and Israel (IM) (NCT03451916)
- 07 Jun 2023 Pluristem terminates a phase II trial in SARS-COV-2 acute respiratory disease in USA (IM) due to the decision to bring the study to early clinical readout came in response to COVID-19's evolution as a disease, and the significant changes in the standard of care, leading to an increase in the severity of conditions of the intubated patients (NCT04389450)
- 06 Sep 2022 Pluristem Therapeutics plans a phase I/IIa trial for Osteoarthritis in